Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0AOJSA
ADC Name
Anti-c-Met IgG-OXA
Synonyms
Anti-MET IgG OXAconjugate
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Hepatocellular carcinoma [ICD11:2C12]
Investigative
Drug-to-Antibody Ratio
4.35
Antibody Name
Anti-MET mAb
  Antibody Info 
Antigen Name
Hepatocyte growth factor receptor (MET)
  Antigen Info 
Payload Name
Oxaliplatin
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Dipeptide-p-amidobenzyl alcohol linker
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 83.4
%
Hep-G2 cells
Hepatoblastoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 83.40% (Day 28) Positive MET expression (MET+++/++)
Method Description
The mice were randomly assigned to groups: those treated with oxaliplatin , anti-c-Met IgG-OXA (10 mg/kg), and vehicle 5% sterile glucose solution. Different drugs were injected intravenously.
In Vivo Model HepG2 CDX model
In Vitro Model Hepatoblastoma Hep-G2 cells CVCL_0027
References
Ref 1 High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma. Front Oncol. 2019 Aug 2;9:717. doi: 10.3389/fonc.2019.00717. eCollection 2019.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.